Renaissance Technologies LLC reduced its stake in Celularity Inc. (NASDAQ:CELU – Free Report) by 14.3% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 25,498 shares of the company’s stock after selling 4,270 shares during the period. Renaissance Technologies LLC’s holdings in Celularity were worth $80,000 at the end of the most recent quarter.
Separately, Keynote Financial Services LLC purchased a new position in shares of Celularity during the 1st quarter worth $81,000. Institutional investors and hedge funds own 19.02% of the company’s stock.
Celularity Trading Up 10.4 %
NASDAQ CELU opened at $2.77 on Tuesday. Celularity Inc. has a twelve month low of $1.59 and a twelve month high of $7.97. The stock has a fifty day simple moving average of $2.84 and a 200-day simple moving average of $3.18.
Celularity Profile
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
Read More
- Five stocks we like better than Celularity
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- Trading Stocks: RSI and Why it’s Useful
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Want to see what other hedge funds are holding CELU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celularity Inc. (NASDAQ:CELU – Free Report).
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.